Cantor Fitzgerald Forecasts Omeros FY2026 Earnings

Omeros Co. (NASDAQ:OMER) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Omeros in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer anticipates that the biopharmaceutical company will post earnings per share of ($1.14) for the year. The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share.

Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.05).

Several other equities analysts have also recently commented on OMER. Wall Street Zen cut shares of Omeros from a “hold” rating to a “sell” rating in a research report on Friday, June 6th. D. Boral Capital restated a “buy” rating and set a $36.00 price target on shares of Omeros in a research note on Tuesday, May 13th. HC Wainwright started coverage on shares of Omeros in a research note on Tuesday. They set a “buy” rating and a $9.00 price target for the company. Finally, Needham & Company LLC restated a “hold” rating on shares of Omeros in a research note on Friday, May 16th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Omeros currently has an average rating of “Moderate Buy” and an average price target of $18.00.

Omeros Stock Down 6.7%

Omeros stock opened at $3.62 on Tuesday. Omeros has a 52 week low of $2.97 and a 52 week high of $13.60. The company’s 50 day moving average price is $5.23 and its two-hundred day moving average price is $7.85. The stock has a market cap of $212.11 million, a P/E ratio of -1.57 and a beta of 2.20.

Institutional Investors Weigh In On Omeros

Several large investors have recently modified their holdings of OMER. New York State Common Retirement Fund increased its stake in shares of Omeros by 245.4% during the 4th quarter. New York State Common Retirement Fund now owns 17,313 shares of the biopharmaceutical company’s stock worth $171,000 after purchasing an additional 12,300 shares during the last quarter. US Bancorp DE purchased a new position in Omeros in the 4th quarter valued at approximately $81,000. Raymond James Financial Inc. purchased a new position in Omeros in the 4th quarter valued at approximately $124,000. AlphaQuest LLC purchased a new position in Omeros in the 4th quarter valued at approximately $285,000. Finally, Truvestments Capital LLC grew its stake in Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 1,669 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.